You may get additional info about cotara from the Peregrine Pharmaceuticals web site. www.peregrineinc.com
Cotara® is an antibody attached to a radioactive molecule. Like a guided missile, the antibody is designed to target specific features at the core of a tumor to deliver a radioactive isotope to kill the tumor literally from the inside out.
Peregrine is working in collaboration with New Approaches to Brain Tumor Therapy (NABTT), a brain cancer consortium funded by the National Cancer Institute, to conduct a clinical trial designed to further evaluate safety and efficacy of a single Cotara infusion in patients with first or second recurrence of glioblastoma multiforme, a particularly deadly form of brain cancer. Cotara has been granted orphan drug status for the treatment of two very different forms of brain cancers -- glioblastoma multiforme and anaplastic astrocytoma.
The trial is designed to treat up to 28 patients, although the study may be expanded as it progresses. Patients who have had prior surgery, chemotherapy, or some forms of radiation treatment may be eligible for the trial. However, patients may be excluded if they have received radiosurgery, brachytherapy, gliadel wafers (implanted wafers containing chemotherapeutic) or other local therapies.
If you are a health care provider interested in referring a patient or learning more about these clinical trials, please send an email correspondence to Peregrine Pharmaceuticals at clinicalaffairs@peregrineinc.com This e-mail address is being protected from spam bots, you need JavaScript enabled to view it clinicalaffairs@peregrineinc.com This e-mail address is being protected from spam bots, you need JavaScript enabled to view it or visit ClinicalTrials.gov.
If you are a patient interested in participating in these trials, please have your personal physician send an email correspondence to Peregrine.